Higher body mass index may be a predictor of extrathyroidal extension in patients with papillary thyroid microcarcinoma

Endocrine

Volumn 48, Issue 1, 2015, Pages 264-271

  Choi, Ji Soo ^a,b   Kim, Eun Kyung ^a   Moon, Hee Jung ^a   Kwak, Jin Young ^a  

^a Yonsei University College of Medicine   (South Korea)

^b Samsung Medical Center   (South Korea)

Author keywords

Body mass index (BMI); Extrathyroidal extension; Obesity; Thyroid cancer; Thyroid malignancy

Indexed keywords

THYROTROPIN;

ADULT; AGED; BLOOD; BODY MASS; CANCER STAGING; CARCINOMA, PAPILLARY; ECHOGRAPHY; ENDOCRINE SURGERY; FEMALE; HUMAN; LYMPH NODE METASTASIS; MALE; MIDDLE AGED; PATHOLOGY; PROGNOSIS; RETROSPECTIVE STUDY; RISK FACTOR; STANDARD; THYROID NEOPLASMS;

ADULT; AGED; BODY MASS INDEX; CARCINOMA, PAPILLARY; ENDOCRINE SURGICAL PROCEDURES; FEMALE; HUMANS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; REFERENCE STANDARDS; RETROSPECTIVE STUDIES; RISK FACTORS; THYROID NEOPLASMS; THYROTROPIN;

EID: 84939885299     PISSN: 1355008X     EISSN: 15590100     Source Type: Journal    
DOI: 10.1007/s12020-014-0293-z     Document Type: Article

References (37)

1. L. Davies, H.G. Welch, Increasing incidence of thyroid cancer in the United States, 1973–2002. JAMA 295(18), 2164–2167 (2006). doi:10.1001/jama.295.18.2164
2. B.A. Kilfoy, T. Zheng, T.R. Holford, X. Han, M.H. Ward, A. Sjodin, Y. Zhang, Y. Bai, C. Zhu, G.L. Guo, N. Rothman, Y. Zhang, International patterns and trends in thyroid cancer incidence, 1973-2002. Cancer Causes Control 20(5), 525–531 (2009). doi:10.1007/s10552-008-9260-4
3. C. Hedinger, E.D. Williams, L.H. Sobin, The WHO histological classification of thyroid tumors: a commentary on the second edition. Cancer 63(5), 908–911 (1989)
4. S. Noguchi, H. Yamashita, S. Uchino, S. Watanabe, Papillary microcarcinoma. World J. Surg. 32(5), 747–753 (2008). doi:10.1007/s00268-007-9453-0
5. American Thyroid Association Guidelines Taskforce on Thyroid, N., Differentiated Thyroid, C., Cooper, D.S., Doherty, G.M., Haugen, B.R., Kloos, R.T., Lee, S.L., Mandel, S.J., Mazzaferri, E.L., McIver, B., Pacini, F., Schlumberger, M., Sherman, S.I., Steward, D.L., Tuttle, R.M.: Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid: official journal of the American Thyroid Association 19(11), 1167–1214 (2009). doi:10.1089/thy.2009.0110
6. R. Gallicchio, S. Giacomobono, D. Capacchione, A. Nardelli, F. Barbato, A. Nappi, T. Pellegrino, G. Storto, Should patients with remnants from thyroid microcarcinoma really not be treated with iodine-131 ablation? Endocrine 44(2), 426–433 (2013). doi:10.1007/s12020-013-9935-9
7. J. Lee, J.H. Park, C.R. Lee, W.Y. Chung, C.S. Park, Long-term outcomes of total thyroidectomy versus thyroid lobectomy for papillary thyroid microcarcinoma: comparative analysis after propensity score matching. Thyroid 23(11), 1408–1415 (2013). doi:10.1089/thy.2012.0463
8. L. Wartofsky, Should patients with papillary microcarcinoma undergo radioiodine ablation? Endocrine 44(2), 278–279 (2013)
9. N. Neuhold, A. Schultheis, M. Hermann, G. Krotla, O. Koperek, P. Birner, Incidental papillary microcarcinoma of the thyroid–further evidence of a very low malignant potential: a retrospective clinicopathological study with up to 30 years of follow-up. Ann. Surg. Oncol. 18(12), 3430–3436 (2011). doi:10.1245/s10434-011-1663-x
10. C. Cappelli, M. Castellano, M. Braga, E. Gandossi, I. Pirola, E. De Martino, B. Agosti, E.A. Rosei, Aggressiveness and outcome of papillary thyroid carcinoma (PTC) versus microcarcinoma (PMC): a mono-institutional experience. J. Surg. Oncol. 95(7), 555–560 (2007). doi:10.1002/jso.20746
11. M.R. Pelizzo, I.M. Boschin, A. Toniato, A. Piotto, P. Bernante, C. Pagetta, L. Rampin, D. Rubello, Papillary thyroid microcarcinoma (PTMC): prognostic factors, management and outcome in 403 patients. Eur. J. Surg. Oncol. 32(10), 1144–1148 (2006). doi:10.1016/j.ejso.2006.07.001
12. A.G. Renehan, M. Tyson, M. Egger, R.F. Heller, M. Zwahlen, Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet 371(9612), 569–578 (2008). doi:10.1016/S0140-6736(08)60269-X
13. P. Brindel, F. Doyon, F. Rachedi, J.L. Boissin, J. Sebbag, L. Shan, V. Chungue, F. Bost-Bezeaud, P. Petitdidier, J. Paoaafaite, J. Teuri, F. de Vathaire, Anthropometric factors in differentiated thyroid cancer in French Polynesia: a case-control study. Cancer Causes Control 20(5), 581–590 (2009). doi:10.1007/s10552-008-9266-y
14. C.M. Kitahara, E.A. Platz, L.E. Freeman, A.W. Hsing, M.S. Linet, Y. Park, C. Schairer, A. Schatzkin, J.M. Shikany, A. de Berrington Gonzalez, Obesity and thyroid cancer risk among US men and women: a pooled analysis of five prospective studies. Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive. Oncology 20(3), 464–472 (2011). doi:10.1158/1055-9965.EPI-10-1220
15. S.W. Oh, Y.S. Yoon, S.A. Shin, Effects of excess weight on cancer incidences depending on cancer sites and histologic findings among men: Korea National Health Insurance Corporation Study. J. Clin. Oncol. 23(21), 4742–4754 (2005). doi:10.1200/JCO.2005.11.726
16. C.L. Amling, R.H. Riffenburgh, L. Sun, J.W. Moul, R.S. Lance, L. Kusuda, W.J. Sexton, D.W. Soderdahl, T.F. Donahue, J.P. Foley, A.K. Chung, D.G. McLeod, Pathologic variables and recurrence rates as related to obesity and race in men with prostate cancer undergoing radical prostatectomy. J. Clin. Oncol. 22(3), 439–445 (2004). doi:10.1200/JCO.2004.03.132
17. E.E. Calle, C. Rodriguez, K. Walker-Thurmond, M.J. Thun, Overweight, obesity, and mortality from cancer in a prospectively studied cohort of US adults. N. Engl. J. Med. 348(17), 1625–1638 (2003). doi:10.1056/NEJMoa021423
18. K.M. Hahn, M.L. Bondy, M. Selvan, M.J. Lund, J.M. Liff, E.W. Flagg, L.A. Brinton, P. Porter, J.W. Eley, R.J. Coates, Factors associated with advanced disease stage at diagnosis in a population-based study of patients with newly diagnosed breast cancer. Am. J. Epidemiol. 166(9), 1035–1044 (2007). doi:10.1093/aje/kwm177
19. A. Harari, B. Endo, S. Nishimoto, P.H. Ituarte, M.W. Yeh, Risk of advanced papillary thyroid cancer in obese patients. Arch. Surg. 147(9), 805–811 (2012). doi:10.1001/archsurg.2012.713
20. H.J. Kim, N.K. Kim, J.H. Choi, S.Y. Sohn, S.W. Kim, S.M. Jin, H.W. Jang, S. Suh, Y.K. Min, J.H. Chung, S.W. Kim, Associations between body mass index and clinico-pathological characteristics of papillary thyroid cancer. Clin. Endocrinol. 78(1), 134–140 (2013). doi:10.1111/j.1365-2265.2012.04506.x
21. S.B. Edge, AJCC cancer staging manual, 7th ed. by B. Stephen Edge et al. (Springer, New York, 2010)
22. J.Y. Kwak, E.K. Kim, J.H. Youk, M.J. Kim, E.J. Son, S.H. Choi, K.K. Oh, Extrathyroid extension of well-differentiated papillary thyroid microcarcinoma on US. Thyroid 18(6), 609–614 (2008). doi:10.1089/thy.2007.0345
23. D.G. Na, H.K. Lim, H.S. Byun, H.D. Kim, Y.H. Ko, J.H. Baek, Differential diagnosis of cervical lymphadenopathy: usefulness of color Doppler sonography. AJR Am. J. Roentgenol. 168(5), 1311–1316 (1997). doi:10.2214/ajr.168.5.9129432
24. P.W. Rosario, S. de Faria, L. Bicalho, M.F. Alves, M.A. Borges, S. Purisch, E.L. Padrao, L.L. Rezende, A.L. Barroso, Ultrasonographic differentiation between metastatic and benign lymph nodes in patients with papillary thyroid carcinoma. J. Ultrasound Med. 24(10), 1385–1389 (2005)
25. M. Ying, A. Ahuja, C. Metreweli, Diagnostic accuracy of sonographic criteria for evaluation of cervical lymphadenopathy. J. Ultrasound Med. 17(7), 437–445 (1998)
26. P.E. Andersen, J. Kinsella, T.R. Loree, A.R. Shaha, J.P. Shah, Differentiated carcinoma of the thyroid with extrathyroidal extension. Am. J. Surg. 170(5), 467–470 (1995)
27. E.L. Mazzaferri, S.M. Jhiang, Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am. J. Med. 97(5), 418–428 (1994)
28. J.A. Sipos, E.L. Mazzaferri, Thyroid cancer epidemiology and prognostic variables. Clin. Oncol. 22(6), 395–404 (2010). doi:10.1016/j.clon.2010.05.004
29. M. Akinci, F. Kosova, B. Cetin, S. Aslan, Z. Ari, A. Cetin, Leptin levels in thyroid cancer. Asian J. Surg./Asian Surg. Assoc. 32(4), 216–223 (2009). doi:10.1016/S1015-9584(09)60397-3
30. F. Balkan, E.D. Onal, A. Usluogullari, D. Tuzun, D. Ozdemir, S.S. Inancli, R. Ersoy, B. Cakir, Is there any association between insulin resistance and thyroid cancer?: a case control study. Endocrine 45(1), 55–60 (2014). doi:10.1007/s12020-013-9942-x
31. S.P. Cheng, C.W. Chi, C.Y. Tzen, T.L. Yang, J.J. Lee, T.P. Liu, C.L. Liu, Clinicopathologic significance of leptin and leptin receptor expressions in papillary thyroid carcinoma. Surgery 147(6), 847–853 (2010). doi:10.1016/j.surg.2009.11.004
32. L. Dossus, R. Kaaks, Nutrition, metabolic factors and cancer risk. Best Prac. Res. Clin. Endocrinol. Metab. 22(4), 551–571 (2008). doi:10.1016/j.beem.2008.08.003
33. S.D. Hursting, L.M. Lashinger, K.W. Wheatley, C.J. Rogers, L.H. Colbert, N.P. Nunez, S.N. Perkins, Reducing the weight of cancer: mechanistic targets for breaking the obesity-carcinogenesis link. Best Prac. Res. Clin. Endocrinol. Metab. 22(4), 659–669 (2008). doi:10.1016/j.beem.2008.08.009
34. N. Mitsiades, K. Pazaitou-Panayiotou, K.N. Aronis, H.S. Moon, J.P. Chamberland, X. Liu, K.N. Diakopoulos, V. Kyttaris, V. Panagiotou, G. Mylvaganam, S. Tseleni-Balafouta, C.S. Mantzoros, Circulating adiponectin is inversely associated with risk of thyroid cancer: in vivo and in vitro studies. J. Clin. Endocrinol. Metab. 96(12), E2023–E2028 (2011). doi:10.1210/jc.2010-1908
35. J.S. Choi, W.Y. Chung, J.Y. Kwak, H.J. Moon, M.J. Kim, E.K. Kim, Staging of papillary thyroid carcinoma with ultrasonography: performance in a large series. Ann. Surg. Oncol. 18(13), 3572–3578 (2011). doi:10.1245/s10434-011-1783-3
36. D.S. McLeod, K.F. Watters, A.D. Carpenter, P.W. Ladenson, D.S. Cooper, E.L. Ding, Thyrotropin and thyroid cancer diagnosis: a systematic review and dose-response meta-analysis. J. Clin. Endocrinol. Metab. 97(8), 2682–2692 (2012). doi:10.1210/jc.2012-1083
37. M.R. Haymart, D.J. Repplinger, G.E. Leverson, D.F. Elson, R.S. Sippel, J.C. Jaume, H. Chen, Higher serum thyroid stimulating hormone level in thyroid nodule patients is associated with greater risks of differentiated thyroid cancer and advanced tumor stage. J. Clin. Endocrinol. Metab. 93(3), 809–814 (2008). doi:10.1210/jc.2007-2215